These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36636635)

  • 21. Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A
    Puig L; Zhu B; Burge R; Shrom D; Dong Y; Shen W; Mallbris L; Reich K
    J Clin Aesthet Dermatol; 2020 Oct; 13(10):18-22. PubMed ID: 33584952
    [No Abstract]   [Full Text] [Related]  

  • 22. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
    Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab.
    Houghton K; Patil D; Gomez B; Feldman SR
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1373-1384. PubMed ID: 34110605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
    Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Papanastasiou P; Bao W; Forrer P; Patekar M
    Paediatr Drugs; 2022 Jul; 24(4):377-387. PubMed ID: 35698000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study.
    Nguyen HT; Pham NTU; Tran TNA; Pham NN; Bui YT; Vu TTP
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):465-476. PubMed ID: 36472791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.
    Chicharro P; Llamas-Velasco M; Armesto S; Herrera-Acosta E; Vidal D; Vilarrasa E; Rivera R; De la Cueva P; Martorell-Calatayud A; Ballescà F; Belinchón I; Carretero G; Rodríguez L; Romero-Maté A; Pujol-Montcusí J; Salgado L; Sahuquillo-Torralba A; Coto-Segura P; Baniandrés-Rodríguez O; Feltes R; Alsina M; Daudén E
    Dermatol Ther; 2022 Aug; 35(8):e15653. PubMed ID: 35731640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
    Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.
    Warren RB; Brnabic A; Saure D; Langley RG; See K; Wu JJ; Schacht A; Mallbris L; Nast A
    Br J Dermatol; 2018 May; 178(5):1064-1071. PubMed ID: 29171861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy.
    Al-Oudah GA; Sahib AS; Al-Hattab MK; Al-Ameedee AA
    J Popul Ther Clin Pharmacol; 2022; 29(2):e52-e60. PubMed ID: 35848197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
    Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
    J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
    [No Abstract]   [Full Text] [Related]  

  • 38. Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.
    Poulin Y; Sheth P; Gu Y; Teixeira HD
    Dermatol Ther (Heidelb); 2014 Jun; 4(1):33-42. PubMed ID: 24488828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
    Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
    Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.
    Richard MA; Lacour JP; Konstantinou MP; Ruer-Mulard M; Joly P; Aractingi S; Auquier P; Pelvet B; Augustin ML; Mahé E; Chalmers RJG
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):677-684. PubMed ID: 32815591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.